Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study
U and NU adenoCAs revealed differences in GA, with <i>PIK3CA</i> and <i>ERBB2</i> being identified as putative therapeutic targets. Biomarkers of response to anti-PD-(L)1 were uncommon. Results highlight the potential of CGP to personalize treatment options of bladder adenoCa and inform clinical trial designs.
Authors
- Gennady Bratslavsky (ORCID: https://orcid.org/0000-0002-2712-4375)
- Valentina Tateo (ORCID: https://orcid.org/0000-0002-1199-2338)
- Petros D. Grivas (ORCID: https://orcid.org/0000-0003-3965-3394)
- Alina Basnet (ORCID: https://orcid.org/0000-0002-6033-6943)
- Dean C. Pavlick (ORCID: https://orcid.org/0000-0001-6075-6246)
- Philippe E. Spiess (ORCID: https://orcid.org/0000-0002-5723-1972)
- Ashish M. Kamat (ORCID: https://orcid.org/0000-0003-3546-9928)
- Antonio Cigliola (ORCID: https://orcid.org/0009-0005-7109-2429)
- Douglas I. Lin (ORCID: https://orcid.org/0000-0003-0105-9760)
- Joseph M Jacob (ORCID: https://orcid.org/0000-0001-8769-2086)
- Andrea Necchi (ORCID: https://orcid.org/0000-0002-3007-2756)
- Chiara Mercinelli (ORCID: https://orcid.org/0000-0003-1165-1776)
- Jeffrey S. Ross (ORCID: https://orcid.org/0000-0001-8494-2596)
- Liang Cheng (ORCID: https://orcid.org/0000-0001-6049-5293)
- Damiano Alfio Patanè
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Vita-Salute San Raffaele University (IT)
- University of Washington (US)
- SUNY Upstate Medical University (US)
- Brown University (US)
- Moffitt Cancer Center (US)
- Fred Hutch Cancer Center (US)
- Lifespan (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- Foundation Medicine (United States)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1200/po.24.00200
- Citations
- 5
- Primary Topic
- Urinary and Genital Oncology Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.86